Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590615 · ClinicalTrials.gov registry record
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 54
- Enrollment target
NCT01590615: Completed study, sponsored by Gilead Sciences.
NCT01590615 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01590615 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.
Primary Outcome
The proportion of participants with a confirmed increase in serum creatinine of at least one grade will be calculated as the number of participants with at least one grade increase in serum creatinine from baseline divided by the total number of subjects enrolled over the 4 years of accrual.
Interventions
- DRUG Anti-HBV nucleoside/nucleotide therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-04-26 |
| Est. Completion | 2017-04-04 |
What the finished NCT01590615 record still lists
NCT01590615 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Anti-HBV nucleoside/nucleotide therapy is the first listed.
NCT01590615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01590615 about?
NCT01590615 is a clinical study titled "Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy". This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.
What is the current status of trial NCT01590615?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2012-04-26. Estimated completion is 2017-04-04.
What interventions are being tested in trial NCT01590615?
The interventions under investigation include: Anti-HBV nucleoside/nucleotide therapy (DRUG).
Who is sponsoring clinical trial NCT01590615?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI